Arrayit Corporation announced receipt of a new clinical licensure from the Centers for Medicare and Medicaid Services (CMS), which oversees the Clinical Laboratory Improvement Amendments (CLIA) Program. Arrayit’s new CLIA license, issued in conjunction with the Department of Health and Human Services (HHS) and the California Department of Public Health (CDPH), provides certification for its Silicon Valley clinical laboratory. Arrayit has developed patented and proprietary microarray technology, validated through the CLIA program, to measure immunoglobulin E (IgE) and immunoglobulin G (IgG) levels for the purposes of allergy and dietary wellness testing. Arrayit tests employ non-invasive finger stick blood sampling, blood cards and a highly miniaturized and automated microarray format to deliver results accurately and quickly. The company enters the $3.2 trillion US healthcare market by offering its tests to hospitals, health maintenance organizations (HMOs), clinical laboratories, physician groups with patients covered by private and government health insurance, and consumers through the assistance of a medical doctor.